Measles virus causes immunogenic cell death in human melanoma [PDF]
, 2011 Oncolytic viruses (OV) are promising treatments for cancer, with several currently undergoing testing in randomised clinical trials. Measles virus (MV) has not yet been tested in models of human melanoma.
Bond, Jacquelyn +14 more
core +1 more source
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model. [PDF]
, 2020 Prodrug activator gene therapy mediated by murine leukemia virus (MLV)-based retroviral replicating vectors (RRV) was previously shown to be highly effective in killing glioma cells both in culture and in vivo.
Chang, Deching +13 more
core +2 more sources
Current landscape and perspective of oncolytic viruses and their combination therapies
Translational Oncology, 2022 Oncolytic virotherapy has become an important strategy in cancer immunotherapy. Oncolytic virus (OV) can reshape the tumor microenvironment (TME) through its replication-mediated oncolysis and transgene-produced anticancer effect, inducing an antitumor ...
Yinghan Su, Changqing Su, Lunxiu Qin
doaj +1 more source
Immunotherapeutic potential of oncolytic vaccinia virus [PDF]
, 2014 The concept of oncolytic viral therapy was based on the hypothesis that engineering tumor-selectivity into the replication potential of viruses would permit direct destruction of tumor cells as a result of viral-mediated lysis, resulting in amplification
Thorne, SH
core +1 more source
Nature CommunicationsOncolytic virotherapy holds promise for cancer treatment, but the factors determining its oncolytic activity remain unclear. Neutrophil extracellular traps (NETs) are associated with cancer progression, yet their formation mechanism and role in oncolytic
Weiwei Dai +14 more
doaj +1 more source
Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression [PDF]
, 2017 Immune-mediated effector molecules can limit cancer growth, but lack of sustained immune activation in the tumour microenvironment restricts antitumour immunity.
Gassa, Asmae +8 more
core +1 more source
An evaluation of the efficacy of adenovirus-mediated gene therapy with p53 for the treatment of cancer [PDF]
, 2015 Cancer is the second leading cause of mortality in the United States today, and equally prevalent throughout the world. Traditional treatments such as chemotherapy and radiotherapy have thus far proven unable to treat the disease with high efficacy, with
Liepart IV, George Hampson
core +1 more source
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [PDF]
, 2016 Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so that they can
Bhatia, Shilpa +4 more
core +3 more sources
TGF-β Inhibition Improves Oncolytic Herpes Viroimmunotherapy in Murine Models of Rhabdomyosarcoma
Molecular Therapy: Oncolytics, 2017 Oncolytic viruses are an emerging class of cancer therapeutics that couple cytotoxicity with the induction of an anti-tumor immune response. Host-virus interactions are complex and modulated by a tumor microenvironment whose immunosuppressive activities ...
Brian Hutzen +8 more
doaj +1 more source
Scientific Reports, 2023 Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Innovative treatment is required to improve overall survival rates for advanced NSCLC.
Akira Sakamoto +5 more
doaj +1 more source